A Phase II, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification.

Trial Profile

A Phase II, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Rigosertib (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Acronyms ONTARGET
  • Sponsors Onconova Therapeutics
  • Most Recent Events

    • 09 Nov 2017 According to an Onconova Therapeutics media release, data from this trial will be presented at the 59th American Society of Hematology (ASH) Annual Meeting 2017.
    • 04 Apr 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 14 May 2015 Enrolment in the extension cohort is complete, according to an Onconova Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top